HCPCS Level II
Q5125
Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram
Codes near Q5125
These sit next to Q5125 in the CMS Level II file. All Q codes
- Q5120Injection, pegfilgrastim-bmez (ziextenzo), biosimilar, 0.5 mg
- Q5121Injection, infliximab-axxq, biosimilar, (avsola), 10 mg
- Q5122Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg
- Q5123Injection, rituximab-arrx, biosimilar, (riabni), 10 mg
- Q5124Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg
- Q5126Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg
- Q5127Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg
- Q5128Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg
- Q5129Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg
- Q5130Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg
NDC crosswalk
| NDC | Drug | Labeler | Billable units |
|---|---|---|---|
| 70121-1568-01 | Releuko | Amneal Pharmaceuticals, LLC | 300 |
| 70121-1568-07 | Releuko | Amneal Pharmaceuticals, LLC | 3000 |
| 70121-1570-01 | Releuko | Amneal Pharmaceuticals, LLC | 480 |
| 70121-1570-07 | Releuko | Amneal Pharmaceuticals, LLC | 4800 |
Source: CMS ASP NDC-HCPCS crosswalk, effective October 1, 2026 through December 31, 2026.